Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Invivyd, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of antibody-based therapies for infectious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on monoclonal antibodies designed to provide protection against rapidly evolving viral threats. Its core value proposition centers on developing antibodies engineered for durability, broad neutralization, and adaptability to viral mutation.
The company’s primary revenue driver to date has been PEMGARDA™ (pemivibart), a monoclonal antibody granted Emergency Use Authorization in the United States for COVID‑19 pre-exposure prophylaxis in certain immunocompromised populations. Invivyd traces its origins to its founding in 2020 as Adagio Therapeutics, Inc., emerging from academic antibody research. The company rebranded as Invivyd, Inc. in 2022 to reflect a broader long-term mission beyond COVID‑19 while maintaining a focus on pandemic preparedness and antibody innovation.
Business Operations
Invivyd operates as a single-segment biotechnology company focused on research and development and, more recently, commercial-stage antibody therapeutics. Revenue generation is currently tied to U.S. sales of PEMGARDA™, while the remainder of operations are devoted to clinical development, regulatory engagement, manufacturing oversight, and lifecycle management of antibody assets. The company does not report multiple operating segments and manages its activities in an integrated structure.
Operations are primarily domestic, with research, development, regulatory, and commercial activities centered in the United States. Invivyd relies on third-party manufacturers for clinical and commercial supply and engages contract research organizations for clinical trials. Based on available public disclosures, the company does not report material operating subsidiaries or joint ventures, and its intellectual property portfolio is internally developed and controlled.
Strategic Position & Investments
Invivyd’s strategic direction is focused on building a rapid-response antibody platform capable of addressing current and future viral threats, particularly in populations underserved by vaccines. The company emphasizes continuous antibody optimization to maintain efficacy against emerging variants, positioning itself as a complementary solution to traditional vaccination strategies.
Investment activity has been concentrated on advancing internal antibody candidates rather than external acquisitions. The company has prioritized capital allocation toward clinical development, regulatory approvals, and commercial infrastructure for PEMGARDA™, as well as next-generation antibodies intended to address variant resistance. Public disclosures do not indicate significant acquisitions or a diversified subsidiary portfolio; data on additional material investments beyond internal R&D programs is inconclusive based on available public sources.
Geographic Footprint
Invivyd is headquartered in Waltham, Massachusetts, and maintains its primary operational presence in the United States. The company’s commercial activities are currently U.S.-focused, aligned with the regulatory authorization and distribution of PEMGARDA™ under U.S. health authorities.
While Invivyd’s antibody development strategy is designed for global relevance, international commercial operations remain limited. Any future expansion outside the United States would depend on additional regulatory authorizations and partnership arrangements. Based on public filings, the company does not report material revenue or operational infrastructure across other continents at this time.
Leadership & Governance
Invivyd is led by an executive team with experience across biotechnology development, commercialization, and corporate strategy. The leadership emphasizes scientific rigor, speed of development, and adaptability to evolving infectious disease landscapes, reflecting the company’s pandemic-response orientation.
Key executives include:
- William Duke – Chief Executive Officer
- Andrew F. Vaughn – Chief Financial Officer
- Dr. Robert B. Finberg – Founder and Chief Scientific Officer
- Dr. Stacy L. Buckley – Chief Medical Officer
The company is governed by a board with experience in biopharmaceutical development and public company oversight. Specific details regarding board committee structure and governance philosophy are disclosed in SEC filings, including annual and proxy statements.